Literature DB >> 3486657

Recombinant tumor necrosis factor depresses cytochrome P450-dependent microsomal drug metabolism in mice.

P Ghezzi, B Saccardo, M Bianchi.   

Abstract

The effect of recombinant tumor necrosis factor on liver cytochrome P450 and related drug metabolism enzymes was investigated. Treatment of mice with tumor necrosis factor caused a marked depression of cytochrome P450 and some drug metabolizing enzymes (ethoxycoumarin deethylase and arylhydrocarbon hydroxylase) in the liver and many other organs. This effect was maximal 24-48 h after treatment and was dependent on the dose of tumor necrosis factor administered. Depression of liver drug metabolizing enzymes was also observed in the endotoxin-resistant C3H/HeJ strain of mice, thus ruling out that this effect may be due to minor endotoxin contamination of recombinant tumor necrosis factor. These data indicate that depression of liver drug metabolism might be an important side effect of tumor necrosis factor, and suggest a role for this macrophage product as an endogenous regulator of liver metabolism.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3486657     DOI: 10.1016/0006-291x(86)90912-5

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

Review 1.  The role of pharmacokinetics in the development of biotechnologically derived agents.

Authors:  R J Wills; B L Ferraiolo
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

2.  Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection.

Authors:  B L Lee; S Safrin; V Makrides; J G Gambertoglio
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

Review 3.  The role of tumor necrosis factor and interleukin 1 in the immunoinflammatory response.

Authors:  J W Larrick; S L Kunkel
Journal:  Pharm Res       Date:  1988-03       Impact factor: 4.200

4.  Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients.

Authors:  B C Israel; R A Blouin; W McIntyre; S I Shedlofsky
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

5.  Immunostimulating lipopeptide, LtriP (RP 56142): comparison of the effect on hepatic cytochrome P 450 modulation and radioprotection in male and female of three mouse strains.

Authors:  M Sedqi; M Delaforge; D Mansuy; B Martin; P Jollès; D Migliore-Samour
Journal:  Experientia       Date:  1995-08-16

6.  Recombinant tumor necrosis factor/cachectin and interleukin 1 pretreatment decreases lung oxidized glutathione accumulation, lung injury, and mortality in rats exposed to hyperoxia.

Authors:  C W White; P Ghezzi; C A Dinarello; S A Caldwell; I F McMurtry; J E Repine
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

7.  Depression of liver metabolism and induction of cytokine release by diphtheria and tetanus toxoids and pertussis vaccines: role of Bordetella pertussis cells in toxicity.

Authors:  G Fantuzzi; M Sironi; R Delgado; L Cantoni; M Rizzardini; M Carelli; I Marsili; P Ghiara; P Ghezzi
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

8.  Effect of whole-body hyperthermia on hepatic cytochrome P450.

Authors:  A J Neville; G Singh
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

9.  Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism.

Authors:  S I Shedlofsky; B C Israel; C J McClain; D B Hill; R A Blouin
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

10.  Interleukin-1 and tumour necrosis factor induce hepatic haem oxygenase. Feedback regulation by glucocorticoids.

Authors:  L Cantoni; C Rossi; M Rizzardini; M Gadina; P Ghezzi
Journal:  Biochem J       Date:  1991-11-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.